GPP
RLAY icon

Great Point Partners’s Relay Therapeutics RLAY Stock Holding History

Great Point Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-658,127
Closed -$10.8M – 50
2023
Q1 		$10.8M Buy
+658,127
New +$11.8M 2.13% 20

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Great Point Partners's RLAY Position: Q2 2023 in Review

Great Point Partners sold out of Relay Therapeutics (RLAY) in Q2 2023, closing a stake of 658,127 shares — an estimated $10.8M sold.

Great Point Partners first reported a position in RLAY in Q1 2023 and held it in 1 quarter. The position peaked at $10.8M in Q1 2023. 161 funds tracked by Wall St. Rank hold RLAY as of Q2 2023.

  • Great Point Partners reported no remaining Relay Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Great Point Partners sold 658,127 Relay Therapeutics shares in Q2 2023, an estimated $10.8M.
  • Great Point Partners first reported a position in Relay Therapeutics in Q1 2023 and held it in 1 quarter.
  • Great Point Partners's Relay Therapeutics position peaked at $10.8M in Q1 2023.
  • 161 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2023.

Based on Great Point Partners's 13F filing for Q2 2023, filed 14 Aug 2023.